Alkermes Plc at JPMorgan Healthcare Conference Transcript
All right, all right. Good morning, everyone. My name is Cory Kasimov, senior biotech analyst at JPMorgan, and it's my pleasure to introduce our next company, which is Alkermes. Here to present for Alkermes is Chairman and CEO, Richard Pops and following Richard's presentation, there's a breakout down the hall to the [left] Olympic room. So with that, turn it over to Rich.
Thank you, Cory, and good morning, everybody. This is a period of intense activity at Alkermes. We've built a $1 billion top line business through developing a series of really important medicines that we're really proud of. But we're now focused on actively shaping the future of this business through an intense assessment of our products, our pipeline and even our corporate structure.
So if you haven't been watching closely, you probably haven't seen a number of the exciting changes that have been occurring, and that's what we're going
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |